VinCaP

Phase II trial of vinflunine chemotherapy in locally advanced and metastatic carcinoma of the penis.

Disease site: Urological cancers

Treatment Modality: Systemic therapy (chemotherapy)

Status: Closed

Trial details

VinCaP is a non-randomised, multicentre, phase II trial to determine the clinical benefit and toxicity of vinflunine chemotherapy in patients with inoperable (locally advanced or metastatic) cancer of the penis. The trial will determine whether this drug warrants further research in this patient group.

Twenty-two evaluable patients will be recruited from UK sites over a two-year period to receive vinflunine (320 mg/m2) every 21 days. Four cycles will be administered prior to formal restaging of disease. Patients with clinical benefit will continue on treatment until disease progression or until toxicity supervenes, or until treatment is discontinued according to clinician or patient decision. Patients will be followed up for a maximum of 24 months.

Further information

Chief Investigator: Dr Lisa Pickering, St George’s Healthcare NHS Trust

Clinical Co-ordinator: Dr Steve Nicholson, Consultant in Medical Oncology, & International Study Chair, International Rare Cancers Initiative in Penile Cancer

ICR-CTSU Statistical Lead: Dr Emma Hall

Trial management contact: [email protected]

Sponsor: The Institute of Cancer Research

View VinCaP on the National Institute for Health Research website: NIHR - Be Part Of Research

Patient friendly information is available from Cancer Research UK

Publications and presentations

There have been no presentations or publications to date.

Image of the Institute of Cancer Research building in Sutton
ICR joins £10million AI project to help identify individual cancer risk

22/01/25

Doctors could soon be able to better predict an individual patient’s chances of getting cancer and offer them personalised detection and prevention strategies, thanks to a new research project co-led by scientists at The Institute of Cancer Research, London.
See full story
MR linac machine - cutting edge scanner
Innovative imaging study confirms feasibility of using smaller target areas in radiotherapy for early-stage glottic cancer

21/01/25

Scientists have successfully used real-time MRI to demonstrate that swallowing causes minimal motion of the larynx, known as the voice box, in people undergoing a radiotherapy session for cancer in this part of the body.
See full story